PL1773314T3 - Zastosowanie L-karnityny do leczenia chorób naczyniowo-sercowych - Google Patents
Zastosowanie L-karnityny do leczenia chorób naczyniowo-sercowychInfo
- Publication number
- PL1773314T3 PL1773314T3 PL05755616T PL05755616T PL1773314T3 PL 1773314 T3 PL1773314 T3 PL 1773314T3 PL 05755616 T PL05755616 T PL 05755616T PL 05755616 T PL05755616 T PL 05755616T PL 1773314 T3 PL1773314 T3 PL 1773314T3
- Authority
- PL
- Poland
- Prior art keywords
- carnitine
- infarction
- treatment
- grams
- days
- Prior art date
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 229960001518 levocarnitine Drugs 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 206010061216 Infarction Diseases 0.000 abstract 2
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000517 death Toxicity 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000346A ITRM20040346A1 (it) | 2004-07-13 | 2004-07-13 | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
| EP05755616A EP1773314B1 (en) | 2004-07-13 | 2005-06-21 | Use of l-carnitine for the treatment of cardiovascular diseases |
| PCT/EP2005/006657 WO2006005415A2 (en) | 2004-07-13 | 2005-06-21 | Use of l-carnitine and glucose for the treatment of cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1773314T3 true PL1773314T3 (pl) | 2012-06-29 |
Family
ID=34971575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05755616T PL1773314T3 (pl) | 2004-07-13 | 2005-06-21 | Zastosowanie L-karnityny do leczenia chorób naczyniowo-sercowych |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7879908B2 (enExample) |
| EP (1) | EP1773314B1 (enExample) |
| JP (1) | JP5230195B2 (enExample) |
| KR (1) | KR101296479B1 (enExample) |
| CN (2) | CN101087602B (enExample) |
| AT (1) | ATE542529T1 (enExample) |
| AU (1) | AU2005262050B2 (enExample) |
| BR (1) | BRPI0513303A8 (enExample) |
| CA (1) | CA2569888C (enExample) |
| CY (1) | CY1112686T1 (enExample) |
| DK (1) | DK1773314T3 (enExample) |
| ES (1) | ES2380913T3 (enExample) |
| HR (1) | HRP20120178T1 (enExample) |
| IT (1) | ITRM20040346A1 (enExample) |
| ME (1) | ME01345B (enExample) |
| MX (1) | MXPA06014665A (enExample) |
| PL (1) | PL1773314T3 (enExample) |
| PT (1) | PT1773314E (enExample) |
| RS (1) | RS52253B (enExample) |
| SI (1) | SI1773314T1 (enExample) |
| WO (1) | WO2006005415A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1120033B (it) * | 1979-10-05 | 1986-03-19 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale |
| JPS6415220A (en) | 1987-07-06 | 1989-01-19 | Mitsubishi Electric Corp | Tension control device for utilizing maximum torque and maximum electric current of winding motor |
| JPH06102624B2 (ja) * | 1990-08-10 | 1994-12-14 | アース製薬株式会社 | 非心臓由来の不整脈防止薬 |
| IT1261695B (it) * | 1993-06-02 | 1996-05-29 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina e alcanoil l-carnitine nella conservazione del sangue per trasfusioni e soluzioni stabilizzatrici che le contengono. |
| US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
| WO2000030637A1 (en) * | 1998-11-26 | 2000-06-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia |
| KR100642731B1 (ko) * | 1999-10-11 | 2006-11-03 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 의료용 용액에서 삼투제로서 ｌ-카르니틴 및 그의알카노일 유도체의 용도 |
| JP4674046B2 (ja) * | 2002-04-01 | 2011-04-20 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | グルコース利用を刺激する化合物および使用方法 |
| ITRM20030178A1 (it) | 2003-04-17 | 2004-10-18 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
-
2004
- 2004-07-13 IT IT000346A patent/ITRM20040346A1/it unknown
-
2005
- 2005-06-21 SI SI200531481T patent/SI1773314T1/sl unknown
- 2005-06-21 PL PL05755616T patent/PL1773314T3/pl unknown
- 2005-06-21 CN CN2005800234751A patent/CN101087602B/zh not_active Expired - Fee Related
- 2005-06-21 EP EP05755616A patent/EP1773314B1/en not_active Expired - Lifetime
- 2005-06-21 MX MXPA06014665A patent/MXPA06014665A/es not_active Application Discontinuation
- 2005-06-21 CA CA2569888A patent/CA2569888C/en not_active Expired - Lifetime
- 2005-06-21 JP JP2007520688A patent/JP5230195B2/ja not_active Expired - Fee Related
- 2005-06-21 AT AT05755616T patent/ATE542529T1/de active
- 2005-06-21 KR KR1020077000711A patent/KR101296479B1/ko not_active Expired - Fee Related
- 2005-06-21 BR BRPI0513303A patent/BRPI0513303A8/pt not_active Application Discontinuation
- 2005-06-21 ES ES05755616T patent/ES2380913T3/es not_active Expired - Lifetime
- 2005-06-21 PT PT05755616T patent/PT1773314E/pt unknown
- 2005-06-21 CN CN201110226409.1A patent/CN102349923B/zh not_active Expired - Fee Related
- 2005-06-21 HR HRP20120178TT patent/HRP20120178T1/hr unknown
- 2005-06-21 WO PCT/EP2005/006657 patent/WO2006005415A2/en not_active Ceased
- 2005-06-21 US US11/629,202 patent/US7879908B2/en not_active Expired - Lifetime
- 2005-06-21 AU AU2005262050A patent/AU2005262050B2/en not_active Ceased
- 2005-06-21 ME MEP-2012-32A patent/ME01345B/me unknown
- 2005-06-21 DK DK05755616.9T patent/DK1773314T3/da active
- 2005-06-21 RS RS20120095A patent/RS52253B/sr unknown
-
2010
- 2010-12-20 US US12/972,617 patent/US8394854B2/en not_active Expired - Fee Related
-
2012
- 2012-04-05 CY CY20121100341T patent/CY1112686T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ravin et al. | Fatal cardiac event following initiation of risperidone therapy | |
| Jaspan et al. | Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| CY1112686T1 (el) | Χρηση l-καρνιτινης για τη θεραπεια καρδιαγγειακων νοσηματων | |
| JPS59116216A (ja) | アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤 | |
| Lappa et al. | Successful treatment of a complicated case of neuroleptic malignant syndrome | |
| CA2493208A1 (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
| MXPA05007612A (es) | Uso de l-carnitina para el tratamiento de enfermedades cardiovasculares. | |
| Petkova et al. | Oral application of sodium pyruvate in healthy persons and patients with diabetes mellitus type I | |
| Poole-Wilson | Timolol maleate (MK 950) in the treatment of essential hypertension | |
| Prabhu et al. | Digital gangrene due to dopamine infusion-a case report | |
| McDaniel | Antidepressant activity of linezolid | |
| JP2008517872A5 (enExample) | ||
| Olgar et al. | Prolonged supine hypertension due to midodrine use in an orthostatic hypotensive child | |
| CN119632990A (zh) | 腔肠素在制备治疗心脏有关疾病的药物中的应用 | |
| Goldberg, B., Levin, NW, Rubinstein, A. & Cohen | Alpha-methyldopa in hypertension | |
| Placebo-Controlled | Original Research Efficacy and Safety of Adjunctive Armodafinil |